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2840 | Nanoscale Adv., 2019, 1, 2840–ermal killing of cancer cells using
LED-activated nucleus targeting ﬂuorescent
carbon dots†
Stephen A. Hill, ‡a Sadiyah Sheikh, ‡a Qiaoyu Zhang,a Lorena Sueiro Ballesteros,b
Andrew Herman,b Sean A. Davis,a David J. Morgan, c Monica Berry,a David Benito-
Alifonsoa and M. Carmen Galan *aThe development of eﬀective theranostic probes in cancer therapy is
hampered due to issues with selectivity and oﬀ-target toxicity. We
report the selective LED-photothermal ablation of cervical (HeLa)
cancer cells over human dermal ﬁbroblasts (HDF) using a new class of
green-emissive ﬂuorescent carbon dots (FCDs). The FCDs can be
easily prepared in one pot using cheap and commercial starting
materials. Physico-chemical characterization revealed that a surface
coating of 2,5-deoxyfructosazine on a robust amorphous core gives
rise to the nanomaterial's unique properties.We show that intracellular
uptake mostly involves passive mechanisms in combination with
intracellular DNA interactions to target the nucleus and that cancer
cell selective killing is likely due to an increase in intracellular
temperature in combinationwith ATP depletion, which is not observed
upon exposure to either the “naked” core FCDs or the surface
components individually. The selectivity of these nanoprobes and the
lack of apparent production of toxicmetabolic byproductsmake these
new nanomaterials promising agents in cancer therapy.Photothermal therapy (PTT) is a promising non-invasive thera-
peutic strategy, in which nanoparticles embedded within
tumors generate heat, typically in response to exogenously
applied light, for thermal ablation of cancer cells.1–3 PTT oﬀers
unique advantages in cancer therapy including high specicity,
minimal invasiveness and precise spatial–temporal selectivity.4
A variety of photothermal nanotherapeutics (PTN) including
noble metal nanostructures, nanocarbons, carbon dots, transi-
tion metal sulde/oxide nanomaterials, and organic nano-antock's Close, Bristol, UK. E-mail: M.C.
, Faculty of Life Sciences Flow Cytometry
emistry, Cardiﬀ University, Park Place,
(ESI) available: Detailed experimental
, XPS, NMR, UV-vis and uorescence
ty and assay characterization data. See
2846agents have been extensively explored with encouraging
results.2,5–9 However, one of the major challenges in PTT is the
ability to selectively and eﬃciently nd a biocompatible mate-
rial that can target cancerous cells while avoiding non-specic
heating of healthy cells upon irradiation and that does not
generate toxic byproducts.5,10
Successful cancer therapy relies on early and accurate diag-
nosis, and uorescence imaging has increasingly been recog-
nized as a viable strategy to identify a range of cancers.11,12
Fluorescent probes that exhibit high stability, sensitivity and
specicity for their target without the limitations of organic
uorophores and uorescent proteins are of great interest in
many areas of research, particularly in cellular biology, bio-
imaging and medical diagnostics.13,14 Nanomaterials with novel
optical, electronic and surface properties, have become useful
platforms for a myriad of applications including imaging, drug
delivery and diagnostics.15–17 Fluorescent carbon dots
(FCDs)18–22 have emerged as a new class of non-isotopic detec-
tion labels suitable for live cell imaging, that provide a non-toxic
alternative to heavymetal-containing uorescent nanomaterials
(e.g. quantum dots) while oﬀering many advantages with regard
to their ease and low cost of synthesis, unique photo-
luminescence (PL) properties, chemical inertness, high water
solubility and generally low cytotoxicity.23–29
Previous work by our group28–34 and others35–38 on the use of
water soluble uorescent probes for live cell imaging applica-
tions has shown that the nanoparticle type, size, shape and
surface functionalization have a signicant eﬀect on their
intracellular uptake and localization. Encouraged by this, we
embarked on the synthesis of a new class of uorescent carbon-
based nanomaterials (FCD-3) with unique surface functionality
that could be used to target cancer cells and have potential
applications in PTT.
Initial eﬀorts were devoted to preparing a green-emitting
nanomaterial that could be more easily imaged directly in live
cells using confocal microscopy than the more common blue-
emitting FCDs.23,26,39–42 The synthesis of FCD-3 was thus ach-
ieved in one pot aer three minutes of microwave heatingThis journal is © The Royal Society of Chemistry 2019
Fig. 1 (A) TEM image of FCD-3 and distribution of diameters between
1.8 and 3 nm. (B) Fluorescence emission and excitation spectra
showing that ﬂuorescence emission is excitation independent.
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View Article Online(domestic 700 W MW) of glucosamine$HCl 1 and m-phenyl-
enediamine 2 (Scheme 1A, see the ESI† for experimental
details).43 Centrifugal ltration (10 kDa molecular weight cut-
oﬀ) aﬀorded monodisperse quasi-spherical FCD-3. The nano-
particles exhibited an average diameter of 2.42  0.55 nm
(Fig. 1A) and an amorphous, carbonaceous core as determined
by high-resolution transmission electron microscopy (HR-TEM,
Fig. S2†). Dynamic light scattering (DLS) indicated a hydrody-
namic diameter of 6–9 nm (Fig. S1A†), while the zeta (electro-
kinetic) potential indicated a cationic surface of around 12 mV
(Fig. S1B†). Thermogravimetric analysis (TGA) showed good
core stability at high temperatures, while residual solvent and
surface-adhered species were more loosely associated (95% of
the mass of FCD-3 was retained when heating to 150 C, while
a 65% mass loss was recorded when reaching 650 C, see
Fig. S3†). Fluorescence spectroscopy showed an excitation-
independent emission for FCD-3 centered around 525 nm (lex
¼ 350–500 nm, Fig. 1B), indicative of emissive center unifor-
mity. The quantum yield for FCD-3 was calculated to be 33%
relative to uorescein (Fig. S4 in the ESI†) and shown to be
photostable upon continuous 60 min irradiation with no
signicant decrease in emission intensity (lex ¼ 460 nm, lem ¼
525 nm, Fig. S5 and S6†).44 The photoluminescence (PL) prop-
erties remained unchanged in the presence of a diﬀerent range
of potential metal and organic quenchers (500 mM), conrming
the stability of FCD-3 (see Fig. S7†).
To ascertain the chemical composition of FCD-3, functional
group analysis was conducted using Fourier-transformed infra-
red (FTIR) spectroscopy, X-ray photoelectron spectroscopy (XPS)
and UV-vis spectroscopy. The FTIR signal at 3338 cm1 was
attributed to either residual carbohydrate architecture (OH
groups) or N–H bonds (Fig. S8†). Surface passivation was evi-
denced by the IR stretching at 1629 cm1 (C]O amide) and
minor peaks at 1016 cm1 (C–O or C–N functionality), while the
broad signal at 612 cm1 indicated C–Cl bonds. The presence of
mainly C, H, N, Cl and O in FCD-3 was also conrmed by
elemental and XPS analysis (Table S1 and Fig. S9†). Peak
deconvolution of each element indicated the likely presence of
a mixture of functionalities, e.g. for O, aliphatic hydroxyl/ether
C–O or ester/imidate O*–C]O/N; aromatic OH or C]O;
for N, amine/N-heteroaromatic motifs or N–C]O bridgedScheme 1 (A) Three minute synthesis of green emitting FCD-3 and (B)
FCD-3 nuclear targeting leading to photothermal cancer cell ablation
after blue-LED irradiation.
This journal is © The Royal Society of Chemistry 2019structures; for C, C–C and C–OH/C–O–C/C–N bonds and minor
peaks as C]O and O–C]O species and for Cl, R–NH3$Cl and
C–Cl motifs (Fig. S10 and Table S2†). Additionally, UV-vis
spectroscopy showed well-dened peaks at 212 nm, 260 nm
(aromatic p–p* transitions), and 370 nm (n–p* aromatic C]C
or C]O/C]N, Fig. S11†), further conrming the presence of
key functional groups.45,46
NMR analysis was used to shed further light on the molec-
ular architectures found on FCD-3 (Fig. S12†). Pyrazine motifs
were identied (three singlets at d 8.51, 8.30 and 5.01 ppm),47 as
probed by 1H, 1H–13C HSQC and HMBC experiments, in addi-
tion to other complex N-hetero/aromatics akin to fructosazine
and likely generated from 1,2-aminoaldose self-dimerisation48
(Fig. S13 and S14†). Polyhydroxylated species (d 2.50–4.00 ppm),
arising from incomplete glycan dehydration,49 were also detec-
ted. Time-point 1H and 13C NMR analysis of reaction aliquots
carried out at 30 s intervals up to 180 s (Fig. S15 and S16 in the
ESI†) showed loss of sugar anomeric signals from the starting
carbohydrate in the spectra, indicative of pyranose ring-opening
and iminium formation, followed by dehydration.29 Other
aromatic structures were also detected in the spectra (d 6.00–
7.50 ppm) suggesting the presence of complex polyaromatics.
Indeed, 1H–13C HMBC analysis demonstrated the presence of
sp2 and sp3-enriched surface domains.
Since nanoparticle surface composition is important for
biological recognition, additional eﬀorts were made to fully
identify the surface molecular structures found on FCD-3. The
material was thus subjected to Sephadex G15 size exclusionNanoscale Adv., 2019, 1, 2840–2846 | 2841
Fig. 2 Colocalisation values (average of global Pearson's correlation)
for FCD-3 treated HeLa cells (50 mg mL1 after 2 h at 37 C) with
diﬀerent organelle-selective ﬂuorescent trackers.
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View Article Onlinechromatography using methanol as the polar solvent to help
separate non-covalently bound surface species from the core-
FCD. In this manner, green uorescent 2,5-deoxyfructosazine
4, which is a known product of glucosamine self-condensa-
tion,50,51 was isolated as the major component in addition to
core FCD-5 (FCD without 4) and FCD-3, as determined by 1H-
NMR of the fractions (Fig. S17–S20† and Scheme 2).52 Zeta
potential measurements of core 5 (1.37) vs. 3 (12.05) showed
a change from a slightly negative net charge to a cationic charge
when 4 is conjugated to the naked core, as expected for
a passivated surface. Moreover, diﬀusion ordered spectroscopy
(DOSY) of FCD-3 showed that it had a single diﬀusion coeﬃ-
cient of 3.83 106 cm2 s1 conrming that 4 is associated with
the FCD-core in FCD-3 (Fig. S20†).
The utility of FCD-3 as a bioimaging tool was then investi-
gated in HeLa cells (cervical cancer) and human dermal bro-
blasts (HDF). It was found that FCD-3 (50 mg mL1) was
internalized in both cell lines, although the rate of uptake and
intracellular localization diﬀered between cell lines. Both active
and passive cell transport mechanisms (37 C vs. 4 C) were
observed, the latter accounting for 67% of uorescence in HeLa,
(Fig. S21†) but only 20% in HDF (Fig. S24 and S25†). Interest-
ingly, very rapid nuclear internalization of FCD-3 was observed
for HeLa cells within 1 min (Fig. S22†), with maximum inter-
nalization at 5 min aer which nuclear uorescence decreased
slightly due to increased cytosolic accumulation which pla-
teaued aer 24 h with an average Global Pearson Coeﬃcient
(GPC) ¼ 0.62 at 2 h exposure (Fig. 2 and 3). No signicant
colocalization of FCD-3 was observed for any other organelle
(for representative images see Fig. S29–S36†). This result is
signicant as previous glucosamine-based blue-emitting
FCDs26,29,33 did not target the cell nucleus. In contrast, much
slower overall cellular uptake of FCD-3 was detected for healthy
HDF cells (Fig. S26 and S27†) with colocalization in the nucleus
only seen aer 2 h of continuous exposure (GPC ¼ 0.50,
Fig. S28†). Similarly, only nuclear and cytosolic accumulation
was detected. These results might be linked to the diﬀerent cell
metabolic ratios associated with cancer vs. non-cancer cell
lines.53
The nucleus contains most of the cell genetic material e.g.
DNA, RNA, rRNA and proteins.54 Thus, it was proposed thatScheme 2 2,5-Deoxyfructosazine 4 was isolated from FCD-3 after
size exclusion chromatography.
2842 | Nanoscale Adv., 2019, 1, 2840–2846favorable electrostatic interactions between FCD-3 and the
phosphate backbone of polynucleotide chains might be
responsible for the nuclear uptake observed. To evaluate this,
cells were incubated with FCD-3 for 2 h at 37 C as before (see
the ESI† for experimental details), before Fo¨rster resonance
energy transfer (FRET) between FCD-3 (FRET donor) and cell
permeable DNA (NuclearID-Red55 and DRAQ-5 (ref. 56)) or RNA
(F22 RNASelect57) intercalating dyes as FRET acceptors was
measured using ow cytometry (Fig. S37–S43†). For both cell
lines, a FRET-associated decrease in emission was observed
between FCD-3 and intercalating DNA-dyes. For instance, in
HeLa cells FCD-3 donor emission decreased by 82% and 60%
with Enzo NuclearID-Red and DRAQ-5 DNA dyes, respectively
(Fig. S40 and S41†), and by 50% and 44% in HDF (Fig. S41 and
S42†).58 On the other hand, no RNA FRET-response was
observed with F22 in HeLa and a minor reduction of 7% was
seen in HDF (Fig. S40 and S43†), suggesting that DNA-mediated
interaction with FCD-3 might be responsible for the observed
internalization.
To evaluate the cytotoxicity of FCD-3, HeLa cells (cervical
cancer) and human dermal broblasts (HDF) were continuously
exposed to FCD-3 at concentrations from 103 to 2000 mg mL1
for 1 h, 1 day, and 3 days (Fig. 4). Metabolic competence was
assessed using Alamar Blue (AB), and the number of live cells
was obtained with calcein. A concentration-dependent toxic
eﬀect was observed in both HeLa and HDF treated cells. For
HeLa, the lethal concentration (LC50) was found to be 100 mg
mL1 aer three days of exposure, while higher concentrations
of FCD-3 were tolerated at shorter exposure times (LC50 at 1 h
was 1500 mg mL1). Reductive metabolism (RM) was halved
aer 1 h of exposure to 500 mg mL1 FCD-3 and to 50 mg mL1
aer three days of exposure (Fig. S44†). In HDF cells (Fig. S45†),
toxicity was detected at higher concentrations and/or longer
exposure times to FCD-3 when compare to HeLa cells. LC50 was
10 times higher and RM50 was observed at 500 mg mL
1 FCD-3
but only aer three days of exposure. The observed diﬀerences
in cytotoxicity for each cell line could be attributed to the
diﬀerent rates of cellular uptake and nuclear accumulation of
FCD-3.
Next, we showed that photothermal activation of FCD-3 (500
mg mL1) in deionized H2O and cell media DMEM (2 mL) wasThis journal is © The Royal Society of Chemistry 2019
Fig. 3 Confocal ﬂuorescence images of HeLa cells after exposure to FCD-3 (50 mg mL1, 2 h). (A) FCD-3 (green); (B) bright ﬁeld; (C) nucleus
tracker (NucRed647); (D) colocalization of FCD-3 and NucRed647 (yellow), (E) positive colocalization in yellow and (F) overlay of all channels.
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View Article Onlinepossible using blue-light-emitting diodes (LEDs), which were
chosen due to their low cost, ease of use, and widespread
availability (lem ¼ 460 nm, Fig. S48†). Encouragingly, a 14 C
increase in temperature was measured aer 90 min of illumi-
nation when compared to illumination of the solvent alone.
Photothermal eﬀects in FCD-3-treated cells post-illumination
were then evaluated. An increase in temperature was alsoFig. 4 HeLa (left) and HDF (right) cells responses to incubation at 37 C
with FCD-3 (0–2000 mg mL1) for 1 h, 1 day or 3 days. (A) Reductive
metabolism (RM); (B) viable cell numbers (calcein). Data referenced to
untreated controls (100%).
This journal is © The Royal Society of Chemistry 2019recorded in the wells of HeLa exposed to FCD-3 for 2 h at room
temperature during the 90 min blue-LED irradiation, when
compared to controls (FCD-3-treated cells kept in the dark). The
temperature increase was proportional to FCD-3 concentration
(Fig. S49†). LED-irradiation of HeLa cells treated with 50 mg
mL1 FCD-3 while keeping the cells at 37 C resulted in
temperatures reaching 56 C aer 90 min, while the same
experiment in HDF cells only recorded 44 C.59
Thermal increases in eukaryotic cells are known to have
detrimental eﬀects and lead to toxicity.60 To evaluate this, HeLa
and HDF cells, cultured in 96-well plates, were exposed to FCD-3
at 1, 10, 50, 100 and 500 mg mL1 for 2 h, before irradiation with
blue LEDs for 30, 60 or 90 min. The FCD-3 containing medium
was then removed and fresh medium was added. Cellular
health was then assessed aer 1 h, 1 day, and 3 days post-
illumination using AB and calcein as before and compared to
controls (cells that have not been exposed to FCD-3 but were
LED-irradiated for the same amount of time). Excitingly,
signicant cell death and decrease in metabolism were
observed for HeLa cells aer incubation with at least 10 mg
mL1 FCD-3 followed by LED-irradiation (Fig. S50–S52†). In
general, cell populations decreased by 75% and 80% aer 1 day
and 3 days post 30 min illumination when using concentrations
as low as 50 mgmL1 FCD-3. Increasing the blue-LED irradiation
time to 60 and 90 min increased the toxic eﬀect in HeLa cells.
Conversely, in 50 mg mL1 FCD-3-treated HDF cells aer 30 min
of illumination, RM was only diminished by 40% aer 3 days
(Fig. S53†) and only aer exposures of up to 500 mg mL1 FCD-3
a population reduction of 60% was observed aer 1 day post-
30 min LED irradiation. Interestingly, at 3 days HDF cells wereNanoscale Adv., 2019, 1, 2840–2846 | 2843
Fig. 6 Percentage of cytosolic DHE ﬂuorescence loss induced by
reactive oxygen species (ROS) after exposure to FCD-3/blue-LED
treatment relative to non-irradiated (dark) controls exposed to equal
concentrations of 3 in (A) HeLa cells and (B) HDF cells.
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View Article Onlinerecovered with only a 20% reduction relative to controls. This
apparent recovery was observed for HDF at all FCD-3 exposure
concentrations and aer all LED-irradiation times (Fig. S54 and
S55†). These diﬀerences in cellular toxicity aer LED illumina-
tion in both cell lines could be attributed to diﬀerences in
photothermal activation which in turn are likely associated to
the diﬀerential cellular uptake of the nanoprobes.
Since FCD-3 contains a robust FCD-core (5) coated with in situ
generated 2,5-deoxyfructosazine 4, and with the knowledge that 4
is a versatile molecule with anti-diabetic and anti-inammatory
properties,50,61 we wanted to determine whether FCD-3 or just 4
alone in solution was responsible for the cell killing eﬀects
observed. To this end, HeLa cells were incubated with FCD-3, 4 or
core FCD-5 at two diﬀerent concentrations (50 and 100 mg mL1
with regard to the concentration of 4) for 2 h at 37 C.62 Following
the same process as before, the cells were then subjected to LED
irradiation or kept in the dark for 60 min aer which cell viability
and metabolism were measured aer 24 and 72 h and compared
to controls (Fig. 5, S56 and S57†). Generally, no signicant toxicity
was observed in cells incubated with either 4 or FCD-5 either in
the dark or under LED illumination, and only cells incubated with
FCD-3 and subjected to LED-illumination showed an 80–90%
reduction in cell viability as before.63
To better understand the mechanism of toxicity, dihy-
droethidium (DHE) was used next to assess the production of
cytosolic reactive oxygen species (ROS) in FCD-3-treated cells 1 h
post illumination. In both HeLa and HDF, ROS production
levels were similar to those of dark controls, except with expo-
sure to FCD-3 of 500 mg mL1 and 90 min illumination which
diminished DHE cytoplasm uorescence by 50% in HeLa cells
(Fig. 6). These results suggest that diﬀerences between HDF and
HeLa responses to FCD-3 exposure/blue-LED illumination are
not likely ROS associated.
Anaerobic glycolysis which produces adequate adenosine 50-
triphosphate (ATP) and biological components is the hall-markFig. 5 HeLa cell viability (calcein) and metabolism (AB) for cells
incubated with FCD-3, 4 or 5 and post 60 min LED irradiation or in the
dark. Data referenced to untreated controls subjected to the same
illumination conditions (shown as 100%).
2844 | Nanoscale Adv., 2019, 1, 2840–2846of cancers to meet the rapid metabolic requirements.64 To
investigate whether ATP levels had been aﬀected upon treat-
ment with FCD-3 and LED irradiation, intracellular ATP levels
were determined in HeLa cells using a luciferin–luciferase
luminescence ATP detection assay. HeLa cells were exposed to
FCD-3 at 1, 10, 50, 100 and 500 mg mL1 and incubated for 2 h
before 90 min blue-LED irradiation. ATP determination was
conducted at 1 h, 1 day and 3 days post-illumination. Controls
kept in the dark did not experience a signicant reduction in
ATP levels aer exposure to FCD-3. However, in cultures irra-
diated with blue-LED, ATP levels were reduced in a concentra-
tion-dependent manner with 1 day and 3 day levels being
diminished by 65% and 75%, respectively, at 1 mg mL1 FCD-3,
relative to dark controls (Fig. 7).
To explore if metabolic products derived from FCD-3 exposure
to cells could induce toxicity, na¨ıve HeLa and HDF cells were
incubated with the supernatant and lysates of FCD-3 exposed
cultures at diﬀerent concentrations (1–500 mg mL1) for 2 h
before 90 min blue-LED illumination. FCD-3 suspended in the
cell culture medium in the absence of cells was irradiated as the
control and RM and live cell numbers were quantied aer 1 day
of exposure. Cell lysates caused no toxic eﬀects in either HeLa or
HDF cells. Supernatants of irradiated HeLa cells were toxic only
at the highest concentration of FCD-3 (500 mg mL1), as deter-
mined by measuring cell viability and reductive metabolism
(Fig. S58 and S59†), while no signicant eﬀects were measured in
HDF cells at all concentrations tested (Fig. S60 and S61†).
Moreover, NMR spectroscopy analysis of pre- and post-90 min
illumination of FCD-3 in water revealed no visible changes in the
structure of the FCDs (Fig. S62†). These results suggest that the
cytotoxicity observed is not likely due to the generation of new
metabolic or photochemical FCD by-products.This journal is © The Royal Society of Chemistry 2019
Fig. 7 ATP depletion in HeLa after 2 h of exposure to FCD-3 followed
by 90 min blue-LED illumination compared to non-irradiated (dark)
controls at equal FCD-3 exposures. ATP luminescence was measured
after cells were washed and after a period of 1 h, 1 day or 3 days under
standard culture conditions.
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View Article OnlineConclusions
In conclusion, we have developed a facile, three minute large-
scale synthesis of a novel green-emissive carbon-based nano-
material FCD-3 that can be used to target HeLa cancer cells
preferentially over healthy epithelial HDF cells under mild
activation conditions. The carbon-based probe contains a stable
amorphous core and is decorated with 2,5-deoxyfructosazine 4
as the major component, which together give rise to the nano-
material's unique properties. We demonstrate that FCD-3 is
internalized into both HeLa and HDF cells partly through
passive mechanisms and traﬃcked into the nucleus by inter-
actions with DNA, albeit at signicantly distinct rates depend-
ing on the cell line. This diﬀerential uptake can be exploited in
the LED-activated selective killing of HeLa over HDF cells aer
60 min of LED-illumination using as little as 50 mg mL1 FCD-3.
The killing is believed to be caused by an increase of intracel-
lular localized temperature followed by ATP depletion. Inter-
estingly, neither the FCD core 5 or surface component 4 are
individually able to induce cancer cell death as observed for
FCD-3. Furthermore, we show that metabolic products from
FCD-3 treated cells do not elicit toxic eﬀects on na¨ıve cells.
These novel metal-free bifunctional nanoprobes have the
potential, with further development, to be eﬀective theranostic
agents in cancer therapy.Conﬂicts of interest
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